By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins has launched an early-exercise warrant incentive program intended to encourage the early exercise of up to 7.8 million of its outstanding unlisted warrants.

The Winnipeg, Manitoba-based firm said that the warrants entitle holders to acquire one share of common stock at a price of C$.10 (US$.10) until June 17, 2011. The warrant holders are now being offered an incentive consisting of a half warrant in addition to the common share issuable for each warrant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.